Lakeside Holding Ltd
For the period ended Dec 31, 2025. Filed Feb 19, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Dec 31, 2025 · Filed Feb 19, 2026
QNME$0.37+9.0%Stored close · as of Nov 6, 2026
Contents
Item 1. Condensed Consolidated Balance Sheets as of December 31, 2025 (unaudited) and June 30, 2025
CONDENSED CONSOLIDATED BALANCE SHEETS
** AS OF DECEMBER 31, 2025 (UNAUDITED) AND JUNE 30, 2025**
| As of December 31, 2025 (unaudited) | As of June 30, 2025 | |
|---|---|---|
| ASSETS | ||
| CURRENT ASSETS | ||
| Cash | $1,641,438 | $4,956,060 |
| Accounts receivable – third parties, net of credit loss allowance of $171,609 and $87,728 | 3,744,551 | 2,895,580 |
| Accounts receivable – related party, net of credit loss allowance of $nil and $nil | 443,941 | 396,331 |
| Note receivable | - | 65,152 |
| Prepayment, deposit and other receivable – third parties | 6,793,122 | 449,977 |
| Other receivable – related party | 1,075,998 | 869,430 |
| Contract assets | 68,912 | 119,054 |
| Inventories, net | 124,336 | 96,534 |
| Right of return asset | 71,518 | 141,687 |
| Loan receivable from related parties | 386,541 | 277,741 |
| Loan receivable from a third party, net of credit loss allowance of $288,000 and $nil | 6,860,622 | 11,380 |
| Total current assets | 21,210,979 | 10,278,926 |
| NON-CURRENT ASSETS | ||
| Long- term investment | 15,741 | 15,741 |
| Property and equipment at cost, net of accumulated depreciation | 362,802 | 389,421 |
| Intangible assets, net | 322,698 | 365,440 |
| Right of use operating lease assets | 2,212,464 | 3,158,202 |
| Right of use financing lease assets | 76,597 | 93,797 |
| Deposit and prepayment | 98,927 | 103,934 |
| Total non-current assets | 3,089,229 | 4,126,535 |
| TOTAL ASSETS | $24,300,208 | $14,405,461 |
| LIABILITIES AND EQUITY | ||
| CURRENT LIABILITIES | ||
| Accounts payables – third parties | $2,899,042 | $2,494,217 |
| Accounts payables – related parties | 200,434 | 65,237 |
| Accrued liabilities and other payables | 2,509,295 | 2,119,994 |
| Current portion of obligations under operating leases | 1,314,019 | 2,323,290 |
| Current portion of obligations under financing leases | 42,273 | 47,035 |
| Loans payable, current | 2,325,149 | 1,300,112 |
| Contract liabilities | 50,783 | 15,355 |
| Tax payable | 407,709 | 312,903 |
| Amounts due to shareholders | 174,626 | - |
| Amounts due to a related party | 260,144 | - |
| Convertible debts - current | 97,162 | 910,675 |
| Refund liabilities | 148,996 | 77,235 |
| Total current liabilities | 10,429,632 | 9,666,053 |
| NON-CURRENT LIABILITIES | ||
| Loans payable, non-current | 117,064 | 60,398 |
| Loan payable to a related party | 124,176 | 124,176 |
| Deferred tax liabilities | 59,606 | 83,100 |
| Obligations under operating leases, non-current | 1,336,300 | 1,559,782 |
| Obligations under financing leases, non-current | 54,739 | 66,267 |
| Total non-current liabilities | 1,691,885 | 1,893,723 |
| TOTAL LIABILITIES | 12,121,517 | 11,559,776 |
| Commitments and Contingencies | ||
| EQUITY | ||
| Common stocks, $0.0001 par value, 200,000,000 shares authorized, 34,427,559 and 10,500,000 issued and outstanding as of December 31, 2025 and June 30, 2025, respectively | 3,443 | 1,050 |
| Subscription receivable | (2,530,508) | - |
| Additional paid-in capital | 22,681,315 | 8,084,275 |
| Statutory reserve | 86,099 | 63,416 |
| Deficits | (8,278,951) | (5,315,371) |
| Accumulated other comprehensive income | 217,293 | 12,315 |
| Total equity | 12,178,691 | 2,845,685 |
| TOTAL LIABILITIES AND EQUITY | $24,300,208 | $14,405,461 |
CONDENSED CONSOLIDATED STATEMENT OF INCOME (LOSS)
AND COMPREHENSIVE INCOME (LOSS)
FOR THE THREE MONTHS AND SIX MONTHS ENDED DECEMBER 31, 2025 AND 2024
| Six Months Ended December 31, | Three Months Ended December 31, | |||
|---|---|---|---|---|
| 2025 | 2024 | 2025 | 2024 | |
| (unaudited) | (unaudited) | (unaudited) | (unaudited) | |
| Revenue from cross-border freight solutions – third party | $8,110,140 | $6,702,063 | $3,928,426 | $3,102,276 |
| Revenue from cross-border freight solutions – related parties | 1,221,728 | 756,994 | 641,568 | 275,227 |
| Revenue from distribution of pharmaceutical products – third parties | 3,780,654 | 218,086 | 2,442,639 | 218,086 |
| Total revenue | 13,112,522 | 7,677,143 | 7,012,633 | 3,595,589 |
| Cost of revenue from cross-border freight solutions – third party | 7,286,059 | 6,153,994 | 3,552,213 | 3,159,709 |
| Cost of revenue from cross-border freight solutions – related party | 822,137 | 921,050 | 355,631 | 356,320 |
| Cost of revenue from pharmaceutical products – third parties | 1,985,266 | 121,791 | 1,194,496 | 121,791 |
| Total cost of revenue | 10,093,462 | 7,196,835 | 5,102,340 | 3,637,820 |
| Gross profit (loss) | 3,019,060 | 480,308 | 1,910,293 | (42,231) |
| Operating expenses: | ||||
| Selling expenses | 1,093,244 | 54,488 | 903,833 | 54,488 |
| General and administrative expenses | 4,318,013 | 3,749,059 | 2,210,358 | 1,911,853 |
| Provision (reversal) of allowance for expected credit loss for accounts receivable | 82,151 | 1,956 | (1,174) | (10,881) |
| Provision of allowance for credit loss on loan receivable from a third party | 288,000 | — | 288,000 | — |
| Total operating expenses | 5,781,408 | 3,805,503 | 3,401,017 | 1,955,460 |
| Loss from operations | (2,762,348) | (3,325,195) | (1,490,724) | (1,997,691) |
| Other income (expense) | ||||
| Other income, net | 282,380 | 201,541 | 135,541 | 91,753 |
| Interest expense | (379,890) | (68,992) | (183,449) | (40,882) |
| Total other income (expense) | (97,510) | 132,549 | (47,908) | 50,871 |
| Loss before income taxes | (2,859,858) | (3,192,646) | (1,538,632) | (1,946,820) |
| Income tax expense | 81,039 | 89,581 | 45,049 | — |
| Net loss attributable to the Company | (2,940,897) | (3,282,227) | (1,583,681) | (1,946,820) |
| Other comprehensive loss: | ||||
| Foreign currency translation income (loss) | 204,978 | (12,186) | 168,050 | (25,179) |
| Comprehensive loss attributable to the Company | $(2,735,919) | $(3,294,413) | $(1,415,631) | $(1,971,999) |
| Loss per share – basic and diluted | $(0.17) | $(0.44) | $(0.08) | $(0.26) |
| Weighted Average Shares Outstanding – basic and diluted | 17,151,720 | 7,500,000 | 19,569,950 | 7,500,000 |
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY
FOR THE THREE MONTHS AND SIX MONTHS ENDED DECEMBER 31, 2025 AND 2024
| Common Shares | Amount | Subscription Receivable | Additional Paid in Capital | Deficits | Accumulated Other Comprehensive Income Loss) | Total | |
|---|---|---|---|---|---|---|---|
| Balance at September 30, 2024 (unaudited) | 7,500,000 | $750 | $— | $4,942,791 | $(1,341,226) | $15,965 | $3,618,280 |
| Net loss | — | — | — | — | (1,946,820) | — | (1,946,820) |
| Foreign currency translation adjustment | — | — | — | — | — | (25,179) | (25,179) |
| Balance at December 31, 2024 (unaudited) | 7,500,000 | $750 | $— | $4,942,791 | $(3,288,046) | $(9,214) | $1,646,281 |
| Common Shares | Amount | Subscription Receivable | Additional Paid in Capital | Deficits | Accumulated Other Comprehensive Income (Loss) | Total | |
|---|---|---|---|---|---|---|---|
| Balance at June 30, 2024 | 6,000,000 | $600 | $(600) | $642,639 | $(5,819) | $2,972 | $639,792 |
| Paid in capital | — | — | 600 | — | — | — | 600 |
| Net loss | — | — | — | — | (3,282,227) | — | (3,282,227) |
| Initial public offering, net of share issuance costs | 1,500,000 | 150 | — | 4,300,152 | — | — | 4,300,302 |
| Foreign currency translation adjustment | — | — | — | — | — | (12,186) | (12,186) |
| Balance at December 31, 2024 (unaudited) | 7,500,000 | $750 | $— | $4,942,791 | $(3,288,046) | $(9,214) | $1,646,281 |
| Common Shares | Amount | Subscription Receivable | Additional Paid in Capital | Statutory Reserves | Deficits | Accumulated Other Comprehensive Income (Loss) | Total | |
|---|---|---|---|---|---|---|---|---|
| Balance at September 30, 2025 (unaudited) | 17,427,559 | $1,743 | $— | $13,512,515 | $74,608 | $(6,683,779) | $49,243 | $6,954,330 |
| Net loss | — | — | — | — | (1,583,681) | — | (1,583,681) | |
| Statutory reserve | — | — | — | 11,491 | (11,491) | — | — | |
| Foreign currency translation gain | — | — | — | — | 168,050 | 168,050 | ||
| Common stock issued for consulting services | 3,000,000 | 300 | — | 2,506,200 | — | — | — | 2,506,500 |
| Issuance of common shares - Private placement | 14,000,000 | 1,400 | (2,530,508) | 6,662,600 | — | — | — | 4,133,492 |
| Balance at December 31, 2025 (unaudited) | 34,427,559 | $3,443 | $(2,530,508) | $22,681,315 | $86,099 | $(8,278,951) | $217,293 | $12,178,691 |
| Common Shares | Amount | Subscription Receivable | Additional Paid in Capital | Statutory Reserves | Deficits | Accumulated Other Comprehensive Income (Loss) | Total | |
|---|---|---|---|---|---|---|---|---|
| Balance at June 30, 2025 | 10,500,000 | $1,050 | $— | $8,084,275 | $63,416 | $(5,315,371) | $12,315 | $2,845,685 |
| Net loss | — | — | — | — | (2,940,897) | — | (2,940,897) | |
| Statutory reserve | — | — | — | 22,683 | (22,683) | — | — | |
| Foreign currency translation gain | — | — | — | — | 204,978 | 204,978 | ||
| Common stock issued for consulting services | 5,300,000 | 530 | — | 4,422,170 | — | — | — | 4,422,700 |
| Issuance of common shares upon exercise of Convertible note | 820,330 | 82 | — | 512,651 | — | — | — | 512,733 |
| Issuance of common shares - Private placement | 17,807,229 | 1,781 | (2,530,508) | 9,662,219 | — | — | — | 7,133,492 |
| Balance at December 31, 2025 (unaudited) | 34,427,559 | $3,443 | $(2,530,508) | $22,681,315 | $86,099 | $(8,278,951) | $217,293 | $12,178,691 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.